(NGNE) Neurogene - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 419m USD | Total Return: 38.6% in 12m
Avg Turnover: 3.30M
Warnings
Interest Coverage Ratio -34615.0 is critical
Choppy
Tailwinds
Shakeout
Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological disorders. The company’s pipeline utilizes adeno-associated virus (AAV) vectors to deliver therapeutic genes, with lead candidates NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease currently in Phase 1/2 clinical trials.
The company operates within the gene therapy sector, a capital-intensive field characterized by high research and development costs and a binary regulatory approval process. Neurogene utilizes a collaborative business model, maintaining licensing agreements with academic and commercial entities such as the University of Edinburgh and Stanford University to access proprietary genetic technologies.
Investors may find ValueRay useful for analyzing the long-term risk-reward profile of clinical-stage biotech assets. Headquartered in New York, the firm focuses on addressing unmet medical needs in pediatric populations where few disease-modifying treatments currently exist.
- Clinical trial data updates for NGN-401 determine valuation in Rett syndrome market
- FDA regulatory pathway clarity for gene therapy candidates impacts long-term commercialization
- Cash runway and capital allocation influence ability to reach late-stage milestones
- Safety profile of AAV9 delivery system dictates progression of clinical pipeline
- Strategic partnerships and licensing agreements drive non-dilutive funding and technology validation
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.31 > 0.02 and ΔFCF/TA -8.80 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.31 > 3% & CFO -81.9m > Net Income -98.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 13.08 > 1.5 & < 3 |
| Outstanding Shares: last quarter (22.3m) vs 12m ago 6.24% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.29%; Δ -0.29% > 0%) |
| Interest Coverage Ratio: -34.6k > 6 (EBIT TTM -103.8m / Interest Expense TTM 3.00k) |
| A: 0.87 (Total Current Assets 246.7m - Total Current Liabilities 18.9m) / Total Assets 263.1m |
| B: -1.46 (Retained Earnings -383.6m / Total Assets 263.1m) |
| C: -0.36 (EBIT TTM -103.8m / Avg Total Assets 289.2m) |
| D: 9.38 (Book Value of Equity 237.8m / Total Liabilities 25.4m) |
| Altman-Z'' = 8.36 = AAA |
As of June 12, 2026, the stock is trading at USD 29.00 with a total of 127,106 shares traded.
Over the past week, the price has changed by +5.53%,
over one month by -6.12%,
over three months by +25.92% and
over the past year by +38.62%.
Neurogene has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy NGNE.
- StrongBuy: 4
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 80 | 175.9% |
P/S = 438.7292
P/B = 1.8275
Revenue TTM = 0.0 USD
EBIT TTM = -103.8m USD
EBITDA TTM = -100.7m USD
Long Term Debt = 6.08m USD (estimated: total debt 9.13m - short term 3.05m)
Short Term Debt = 3.05m USD (from shortTermDebt, last quarter)
Debt = 9.13m USD (from shortLongTermDebtTotal, last quarter) (leases 9.54m already included)
Net Debt = -234.1m USD (calculated: Debt 9.13m - CCE 243.2m)
Enterprise Value = 184.5m USD (418.6m + Debt 9.13m - CCE 243.2m)
Interest Coverage Ratio = -34.6k (Ebit TTM -103.8m / Interest Expense TTM 3.00k)
EV/FCF = -2.23x (Enterprise Value 184.5m / FCF TTM -82.6m)
FCF Yield = -44.76% (FCF TTM -82.6m / Enterprise Value 184.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.19m) / Revenue TTM)
Tobins Q-Ratio = 0.70 (Enterprise Value 184.5m / Total Assets 263.1m)
Interest Expense / Debt = 0.03% (Interest Expense 3.00k / Debt 9.13m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -82.0m (EBIT -103.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 13.08 (Total Current Assets 246.7m / Total Current Liabilities 18.9m)
Debt / Equity = 0.04 (Debt 9.13m / totalStockholderEquity, last quarter 237.8m)
Debt / EBITDA = 2.33 (negative EBITDA) (Net Debt -234.1m / EBITDA -100.7m)
Debt / FCF = 2.83 (negative FCF - burning cash) (Net Debt -234.1m / FCF TTM -82.6m)
Total Stockholder Equity = 260.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.10% (Net Income -98.6m / Total Assets 263.1m)
RoE = -37.88% (Net Income TTM -98.6m / Total Stockholder Equity 260.4m)
RoCE = -38.97% (EBIT -103.8m / Capital Employed (Equity 260.4m + L.T.Debt 6.08m))
RoIC = -33.17% (negative operating profit) (NOPAT -82.0m / Invested Capital 247.3m)
WACC = 12.20% (E(418.6m)/V(427.7m) * Re(12.47%) + D(9.13m)/V(427.7m) * Rd(0.03%) * (1-Tc(0.21)))
Discount Rate = 12.47% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 60.0 | Cagr: 27.89%
[DCF] Fair Price = unknown (Cash Flow -82.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.56 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.39 | Chg30d=-14.27% | Revisions=-56% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-1.31 | Chg30d=-0.67% | Revisions=-33% | Analysts=6
EPS current Year (2026-12-31): EPS=-5.41 | Chg30d=-8.00% | Revisions=-33% | GrowthEPS=-27.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-5.59 | Chg30d=-0.84% | Revisions=-14% | GrowthEPS=-3.4% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -56%